Moderna and Merck Announce Breakthrough in Personalized Cancer Vaccine for Melanoma
Merck and Moderna have reported significant success with a personalized cancer vaccine designed to prevent the recurrence and spread of melanoma. This vaccine, known as intismeran autogene, combines Merck’s immunotherapy drug Keytruda with a customized mRNA vaccine. The mRNA vaccine instructs the immune system to specifically target mutations found only on a patient's tumor, a different approach from traditional chemotherapy or general immunotherapy. A large trial involving over 1,000 melanoma patients, who had surgically removed localized tumors but faced a high risk of recurrence, demonstrated the vaccine's effectiveness. Five-year data from a previous mid-stage trial, presented in June, indicated that the vaccine cut the risk of cancer returning by half and reduced the risk of it spreading to new locations by 59% when compared to Keytruda alone. The companies noted no new side effects with the addition of the vaccine, with reactions similar to those experienced with flu or COVID shots. This development ... 
